Rabies – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Rabies – Pipeline Review, H2 2016’, provides an overview of the Rabies pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rabies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rabies and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rabies

The report reviews pipeline therapeutics for Rabies by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rabies therapeutics and enlists all their major and minor projects

The report assesses Rabies therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rabies

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rabies

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co., Ltd

BioClonetics Immunotherapeutics, Inc.

Celltrion, Inc.

Curevac AG

Humabs BioMed SA

Indian Immunologicals Limited

Kaketsuken K.K.

Kamada Ltd.

Molecular Targeting Technologies, Inc.

NanoViricides, Inc.

Novavax, Inc.

PaxVax, Inc.

Prosetta Biosciences, Inc.

Sanofi Pasteur SA

Serum Institute of India Limited

Sinovac Biotech Ltd.

Synermore Biologics Co Ltd

Trellis Bioscience, Inc.

VBI Vaccines Inc

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Rabies Overview 9

Therapeutics Development 10

Pipeline Products for Rabies - Overview 10

Pipeline Products for Rabies - Comparative Analysis 11

Rabies - Therapeutics under Development by Companies 12

Rabies - Therapeutics under Investigation by Universities/Institutes 14

Rabies - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Rabies - Products under Development by Companies 19

Rabies - Products under Investigation by Universities/Institutes 20

Rabies - Companies Involved in Therapeutics Development 21

Beijing Minhai Biotechnology Co., Ltd 21

BioClonetics Immunotherapeutics, Inc. 22

Celltrion, Inc. 23

Curevac AG 24

Humabs BioMed SA 25

Indian Immunologicals Limited 26

Kaketsuken K.K. 27

Kamada Ltd. 28

Molecular Targeting Technologies, Inc. 29

NanoViricides, Inc. 30

Novavax, Inc. 31

PaxVax, Inc. 32

Prosetta Biosciences, Inc. 33

Sanofi Pasteur SA 34

Serum Institute of India Limited 35

Sinovac Biotech Ltd. 36

Synermore Biologics Co Ltd 37

Trellis Bioscience, Inc. 38

VBI Vaccines Inc 39

Zydus Cadila Healthcare Limited 40

Rabies - Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Combination Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

(Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

CTP-19 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

CV-8102 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

IMT-504 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

KD-357 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

MAb-3 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Monoclonal Antibodies for Rabies - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Monoclonal Antibodies for Rabies - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Monoclonal Antibody for Rabies - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

nadorameran - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

PAV-866 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

RabiCide-I - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

rabies [strain Wistar PM/WI 38-1503-3M] vaccine - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

rabies immune globulin (human) - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

rabies vaccine - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

rabies vaccine - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

rabies vaccine - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

rabies vaccine - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

rabies vaccine - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

rabies vaccine - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

rabies vaccine - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

rabies vaccine - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

rabies vaccine 1 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Rabimabs - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

RVC-20 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

RVC-58 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

SII RMab - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

SO-57 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

SOJB - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

SYN-023 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Rabies - Dormant Projects 83

Rabies - Product Development Milestones 84

Featured News & Press Releases 84

Sep 01, 2016: Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment 84

Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant 84

Dec 23, 2015: Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment 86

Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies 87

Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies 88

Aug 28, 2009: Rabies Vaccine Supply Update: IMOVAX Rabies Vaccine Availability 88

Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel 89

Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America 89

May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product 90

Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company 90

Appendix 91

Methodology 91

Coverage 91

Secondary Research 91

Primary Research 91

Expert Panel Validation 91

Contact Us 91

Disclaimer 92

List of Tables

List of Tables

Number of Products under Development for Rabies, H2 2016 10

Number of Products under Development for Rabies – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Investigation by Universities/Institutes, H2 2016 20

Rabies – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 21

Rabies – Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016 22

Rabies – Pipeline by Celltrion, Inc., H2 2016 23

Rabies – Pipeline by Curevac AG, H2 2016 24

Rabies – Pipeline by Humabs BioMed SA, H2 2016 25

Rabies – Pipeline by Indian Immunologicals Limited, H2 2016 26

Rabies – Pipeline by Kaketsuken K.K., H2 2016 27

Rabies – Pipeline by Kamada Ltd., H2 2016 28

Rabies – Pipeline by Molecular Targeting Technologies, Inc., H2 2016 29

Rabies – Pipeline by NanoViricides, Inc., H2 2016 30

Rabies – Pipeline by Novavax, Inc., H2 2016 31

Rabies – Pipeline by PaxVax, Inc., H2 2016 32

Rabies – Pipeline by Prosetta Biosciences, Inc., H2 2016 33

Rabies – Pipeline by Sanofi Pasteur SA, H2 2016 34

Rabies – Pipeline by Serum Institute of India Limited, H2 2016 35

Rabies – Pipeline by Sinovac Biotech Ltd., H2 2016 36

Rabies – Pipeline by Synermore Biologics Co Ltd, H2 2016 37

Rabies – Pipeline by Trellis Bioscience, Inc., H2 2016 38

Rabies – Pipeline by VBI Vaccines Inc, H2 2016 39

Rabies – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 40

Assessment by Monotherapy Products, H2 2016 41

Assessment by Combination Products, H2 2016 42

Number of Products by Stage and Target, H2 2016 44

Number of Products by Stage and Mechanism of Action, H2 2016 45

Number of Products by Stage and Route of Administration, H2 2016 47

Number of Products by Stage and Molecule Type, H2 2016 49

Rabies – Dormant Projects, H2 2016 83

List of Figures

List of Figures

Number of Products under Development for Rabies, H2 2016 10

Number of Products under Development for Rabies – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 41

Number of Products by Targets, H2 2016 43

Number of Products by Stage and Targets, H2 2016 43

Number of Products by Stage and Mechanism of Actions, H2 2016 45

Number of Products by Routes of Administration, H2 2016 46

Number of Products by Stage and Routes of Administration, H2 2016 46

Number of Products by Top 10 Molecule Types, H2 2016 48

Number of Products by Stage and Top 10 Molecule Types, H2 2016 48

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports